38
Views
0
CrossRef citations to date
0
Altmetric
Corrigendum

EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]

Page 2069 | Published online: 04 Nov 2014
This article refers to:
EMSAM (deprenyl patch): how a promising antidepressant was underutilized

Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.

On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.

On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.

On page 1921 “With over 14 years left in the patent of EMSAM, […]” should be “with 4 years left in the patent of EMSAM, […]”.

The authors apologize for these errors.